
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT
- About
JIN MEDICAL INTERNATIONAL LTD. Ordinary Shares (ZJYL)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: ZJYL (1-star) is currently NOT-A-BUY. Pass it for now.
1 Year Target Price $0
1 Year Target Price $0
0 | Strong Buy |
0 | Buy |
0 | Hold |
0 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 34.41% | Avg. Invested days 22 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 101.74M USD | Price to earnings Ratio 32.49 | 1Y Target Price - |
Price to earnings Ratio 32.49 | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 10.76 | 52 Weeks Range 0.56 - 4.38 | Updated Date 06/29/2025 |
52 Weeks Range 0.56 - 4.38 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.02 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 15.64% | Operating Margin (TTM) 18.61% |
Management Effectiveness
Return on Assets (TTM) 5.78% | Return on Equity (TTM) 13.02% |
Valuation
Trailing PE 32.49 | Forward PE - | Enterprise Value 86163622 | Price to Sales(TTM) 4.33 |
Enterprise Value 86163622 | Price to Sales(TTM) 4.33 | ||
Enterprise Value to Revenue 3.67 | Enterprise Value to EBITDA 21.62 | Shares Outstanding 156547008 | Shares Floating 37824910 |
Shares Outstanding 156547008 | Shares Floating 37824910 | ||
Percent Insiders 75.84 | Percent Institutions 0.64 |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
JIN MEDICAL INTERNATIONAL LTD. Ordinary Shares
Company Overview
History and Background
JIN MEDICAL INTERNATIONAL LTD., founded in China, focuses on research, development, and manufacturing of rehabilitation and homecare medical devices. It initially focused on the Chinese market before expanding internationally. Its history reflects a growth trajectory driven by the increasing demand for home healthcare solutions.
Core Business Areas
- Rehabilitation Equipment: Includes wheelchairs, mobility scooters, and other assistive devices aimed at improving patient mobility and independence.
- Homecare Medical Devices: Comprises a range of products such as hospital beds, respiratory devices, and patient monitoring systems designed for use in home settings.
- Disability Equipment and Assistive Devices: Includes a wide array of assistive devices that help people with disabilities in their day-to-day life
Leadership and Structure
Leadership roles and organizational structure are not readily available for a small company such as this one.
Top Products and Market Share
Key Offerings
- Wheelchairs: Manual and electric wheelchairs are a significant portion of their revenue. Market share data for JIN Medical specifically is difficult to obtain, but the global wheelchair market has key competitors such as Invacare and Permobil.
- Mobility Scooters: Designed for enhanced mobility for elderly or disabled individuals. Market share data is limited for JIN Medical. Top competitors include Pride Mobility and Golden Technologies.
- Hospital Beds: Designed for enhanced comfort, support, and assist in healing. Market share data is limited for JIN Medical. Top competitors include Stryker and Hill-Rom Holdings.
Market Dynamics
Industry Overview
The rehabilitation and homecare medical device market is growing due to an aging population, increasing prevalence of chronic diseases, and advancements in technology. The shift towards home-based healthcare is further driving demand.
Positioning
JIN MEDICAL aims to establish a strong presence in niche markets, focusing on product innovation and competitive pricing to gain market share. The company differentiates itself by focusing on affordable solutions
Total Addressable Market (TAM)
The global medical device market is estimated to be in the hundreds of billions of dollars. JIN MEDICAL's TAM is related to the rehab and homecare sub-segments, positioning them to capture a portion of this market.
Upturn SWOT Analysis
Strengths
- Competitive pricing
- Focus on niche markets
- Product innovation and diversity
- Strong growth potential
Weaknesses
- Limited brand recognition
- Small market share compared to larger competitors
- Dependence on a limited number of suppliers
- Financial performance instability
Opportunities
- Expanding distribution network
- Developing new products
- Entering new geographic markets
- Partnerships and collaborations
Threats
- Intense competition
- Changes in regulations and healthcare policies
- Economic downturns
- Supply chain disruptions
Competitors and Market Share
Key Competitors
- INVACARE CORP (IVC)
- STRYKER CORPORATION (SYK)
- HILL-ROM HOLDINGS, INC. (HRC)
Competitive Landscape
JIN MEDICAL faces intense competition from larger, more established players. Their competitive advantages lie in niche markets and price sensitivity.
Growth Trajectory and Initiatives
Historical Growth: Due to data limitations, historical growth patterns for JIN MEDICAL are not clearly defined. Any analysis cannot be substantiated.
Future Projections: Future projections for JIN MEDICAL are speculative, and cannot be reliably generated with the level of information available.
Recent Initiatives: Recent initiatives are not publicly documented, making it difficult to assess ongoing strategic activities. Further data may be obtained from other sources
Summary
JIN MEDICAL INTERNATIONAL LTD. is a small rehabilitation and homecare medical device company with potential for growth in niche markets due to affordable solutions. However, it faces challenges due to limited brand recognition and intense competition. The company must focus on expanding its distribution network and developing new products to capitalize on opportunities. Additionally, maintaining strong financials and adapting to regulatory changes is critical for sustainable growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Market research reports
- Financial news sources
- SEC Filings
Disclaimers:
The data provided is based on publicly available information. Accuracy is not guaranteed. This analysis is for informational purposes only and should not be considered financial advice. Market share is approximate and based on available estimates.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About JIN MEDICAL INTERNATIONAL LTD. Ordinary Shares
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2023-03-28 | Chairman of the Board, President & CEO Mr. Erqi Wang | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 269 | Website https://www.zhjmedical.com |
Full time employees 269 | Website https://www.zhjmedical.com |
Jin Medical International Ltd. engages in the design, development, manufacture, and sale of wheelchair and other living aids products for people with disabilities, the elderly, and people recovering from injury. The company offers wheelchairs and wheelchair components; oxygen concentrators, bath aids, and rehabilitative devices, as well as infrastructures for shared wheelchairs and other shared health products; oxygen chambers and beauty instruments; and shampoo instruments and nano thermal therapy chambers. It operates in China, Japan, the United States, Hong Kong, Singapore, Korea, Australia, and internationally. The company was founded in 2006 and is based in Changzhou, China. Jin Medical International Ltd. is a subsidiary of Jolly Harmony Enterprises Limited.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.